LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 711 | 4168 | 0.1708 | -0.3524 |
| SK-BR-3 | AT-7519 | 10 | uM | LJP6 | 72 | hr | 1401 | 486 | 4168 | 0.1167 | -0.4930 |
| SK-BR-3 | AZD7762 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1907 | 4168 | 0.4574 | 0.2158 |
| SK-BR-3 | AZD7762 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1526 | 4168 | 0.3660 | 0.0552 |
| SK-BR-3 | AZD7762 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1341 | 4168 | 0.3216 | -0.0285 |
| SK-BR-3 | AZD7762 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1112 | 4168 | 0.2665 | -0.1380 |
| SK-BR-3 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1020 | 4168 | 0.2452 | -0.1849 |
| SK-BR-3 | AZD7762 | 10 | uM | LJP6 | 72 | hr | 1401 | 856 | 4168 | 0.2056 | -0.2694 |
| SK-BR-3 | AZD8055 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1460 | 4168 | 0.3504 | 0.0264 |
| SK-BR-3 | AZD8055 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1438 | 4168 | 0.3455 | 0.0170 |
| SK-BR-3 | AZD8055 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1361 | 4168 | 0.3270 | -0.0182 |
| SK-BR-3 | AZD8055 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1306 | 4168 | 0.3138 | -0.0436 |
| SK-BR-3 | AZD8055 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1289 | 4168 | 0.3097 | -0.0518 |
| SK-BR-3 | AZD8055 | 10 | uM | LJP6 | 72 | hr | 1401 | 443 | 4168 | 0.1063 | -0.5192 |
| SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3852 | 4168 | 0.9237 | 0.9010 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 4043 | 4168 | 0.9705 | 0.9625 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 4190 | 4168 | 1.0057 | 1.0077 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 4107 | 4168 | 0.9848 | 0.9801 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4352 | 4168 | 1.0443 | 1.0563 |
| SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 72 | hr | 1401 | 2693 | 4168 | 0.6469 | 0.5157 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4863 | 4245 | 1.1519 | 1.1903 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4299 | 4245 | 1.0206 | 1.0288 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4613 | 4245 | 1.0928 | 1.1181 |
| SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4261 | 4245 | 1.0100 | 1.0149 |
| SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3557 | 4245 | 0.8426 | 0.7983 |